155 related articles for article (PubMed ID: 33938071)
1. Decrease in CD38
Luce S; Batard T; Bordas-Le Floch V; Le Gall M; Mascarell L
Clin Exp Allergy; 2021 Aug; 51(8):1057-1068. PubMed ID: 33938071
[TBL] [Abstract][Full Text] [Related]
2. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy.
Bordas-Le Floch V; Berjont N; Batard T; Varese N; O'Hehir RE; Canonica WG; van Zelm MC; Mascarell L
Allergy; 2022 Apr; 77(4):1263-1273. PubMed ID: 34551124
[TBL] [Abstract][Full Text] [Related]
3. Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens.
Potapova E; Bordas-Le Floch V; Schlederer T; Vrtala S; Huang HJ; Canonica GW; Valenta R; Matricardi PM; Mascarell L
Allergy; 2022 Oct; 77(10):3084-3095. PubMed ID: 35474582
[TBL] [Abstract][Full Text] [Related]
4. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
[TBL] [Abstract][Full Text] [Related]
6. New Suggestions in Sublingual Immunotherapy for House Dust Mite- Related Allergic Diseases.
Ferrando M; Bagnasco D; Passa-Lacqua G; Puggioni F; Varricchi G; Canonica GW
Curr Pharm Biotechnol; 2017; 18(5):378-383. PubMed ID: 28413977
[TBL] [Abstract][Full Text] [Related]
7. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial.
Virchow JC; Backer V; Kuna P; Prieto L; Nolte H; Villesen HH; Ljørring C; Riis B; de Blay F
JAMA; 2016 Apr; 315(16):1715-25. PubMed ID: 27115376
[TBL] [Abstract][Full Text] [Related]
9. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Baron-Bodo V; Batard T; Nguyen H; Fréreux M; Horiot S; Harwanegg C; Bergmann KC; de Beaumont O; Moingeon P
Clin Exp Allergy; 2012 Oct; 42(10):1510-8. PubMed ID: 22994348
[TBL] [Abstract][Full Text] [Related]
10. Pooled efficacy and safety data for house dust mite sublingual immunotherapy tablets in adolescents.
Matsuoka T; Bernstein DI; Masuyama K; Nolte H; Okamiya K; Seitzberg D; Nelson HS
Pediatr Allergy Immunol; 2017 Nov; 28(7):661-667. PubMed ID: 28660739
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of the SQ house dust mite sublingual immunotherapy-tablet in Japanese adult patients with house dust mite-induced allergic asthma: a randomized, double-blind, placebo-controlled phase I study.
Okamiya K; Sekino H; Azuma R; Kudo M; Sakaguchi M; Nemoto F; Muramatsu N; Maekawa Y; Tanaka A
J Asthma; 2019 Dec; 56(12):1347-1355. PubMed ID: 30444150
[No Abstract] [Full Text] [Related]
12. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
[TBL] [Abstract][Full Text] [Related]
14. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy.
Ihara F; Sakurai D; Yonekura S; Iinuma T; Yagi R; Sakurai T; Ito T; Matsuura A; Morimoto Y; Arai T; Suzuki S; Katayama K; Nakayama T; Okamoto Y
Allergy; 2018 Sep; 73(9):1823-1832. PubMed ID: 29517806
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
Demoly P; Kleine-Tebbe J; Rehm D
Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
17. Preventive sublingual immunotherapy with House Dust Mite extract modulates epitope diversity in pre-school children.
Ponce M; Schroeder F; Bannert C; Schmidthaler K; Hansen CS; Lindholm Bøgh K; Soldo R; Tsui SK; Weinhäusel A; Szépfalusi Z; Eiwegger T
Allergy; 2019 Apr; 74(4):780-787. PubMed ID: 30394551
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
Hesse L; Nawijn MC
Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population.
Okamoto Y; Fujieda S; Okano M; Hida H; Kakudo S; Masuyama K
Pediatr Allergy Immunol; 2019 Feb; 30(1):66-73. PubMed ID: 30281866
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for house-dust mite allergy.
Nelson HS
Allergy Asthma Proc; 2018 Jul; 39(4):264-272. PubMed ID: 30095391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
